Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 2 | Clinical Proteomics

Fig. 2

From: Glycomic Approaches to Study GlcNAcylation: Protein Identification, Site-mapping, and Site-specific O-GlcNAc Quantitation

Fig. 2

O-GlcNAc peptide ionization is suppressed in presence of unmodified peptides. A GlcNAcylated peptide YSPTgSPSK ([M+GlcNAc+H]+ 1069.5) and its unmodified form ([M+H]+ 866.4) are mixed at indicated molar ratios and analyzed by MALDI-TOF using α-cyano-4-hydroxycinnamic acid as the matrix. Arrows point to peaks of m/z 1069.5. B GlcNAcylated peptides coelute with their unmodified forms on reverse-phase HPLC. RF column is packed with a 10-cm-length of C18 beads. Gradient is 5–40% solvent B (solvent A: 0.1% formic acid; solvent B: 90% acetonitrile, 0.1% formic acid) in 60 min at a flow rate of 300 nl/min. Extracted ion chromatograms are shown. Time of elution peaks is as indicated. C GlcNAcylated peptide YSPTgSPSK ([M+GlcNAc+H]+ 1069.5) is mixed with its unmodified form ([M+H]+ 866.4) at indicated molar ratios and sprayed into LCQ mass spectrometer via electrospray ionization. Averaged full scan spectra are shown. Arrows point to peaks of m/z 1069.5. Peaks of m/z 904.5, 918.3, and 942.5 are due to peptide impurities

Back to article page